• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

How to Play Johnson & Johnson Now That Earnings Are Out

There's a lot of runway left to adjust guidance numbers moving forward.
By TIMOTHY COLLINS
Jan 22, 2019 | 02:58 PM EST
Stocks quotes in this article: JNJ

Johnson & Johnson (JNJ) did not do enough to alleviate investor concerns on Tuesday morning. The company nudged past earnings per share estimates of $1.95 by delivering $1.97 on $20.4 billion in revenue. However, the wrinkle came in the form of "lite" guidance.

Management projects 2019 EPS of $8.50-$8.65 versus the consensus estimate of $8.61 with revenue guidance coming in almost $2 billion shy of estimates. That is a little above a 2% miss on revenue. Given that JNJ just reported its fourth-quarter numbers for 2018, there's a lot of runway left to adjust these numbers moving forward. The EPS net is wide enough that JNJ could still deliver in-line or better-than-anticipated earnings plus I believe management is likely taking a conservative approach, so I'm not concerned about guidance.

Growth numbers, backing out negative currency impact, landed in the very low single digits although currency drag makes the headline growth number appear virtually flat for the quarter. Overall sales increased a little more than 6% after adjusting for a positive currency impact. With the 6% revenue growth rate along with the 13% EPS growth rate, JNJ does a fairly decent job at justifying its 2019 P/E ratio around 15, especially once an investor factors in the 2.75% yield along with ongoing $5 billion share repurchase program.

The largest overhang for JNJ is the talc/asbestos claim. I still believe the $40 billion in market cap JNJ has surrendered since mid-December has priced in the majority of a negative finding/liability for the company. I peg the downside at $110 on an initial overreaction with the shares settling in a $115-120 trading range as the company potentially negotiates a settlement. Of course, that's a big if. Unfortunately, until the overhang is removed, we see some clear resistance between $130-$133.

If you aren't already involved in the name, I'd likely remain on the sidelines. For traders on the long side, I would consider using collars or covered calls against your long share position. Collars are becoming more attractive as volatility continues to get sucked away from JNJ shares, especially with earnings now behind the company.

However, until the talc issues are clarified the risk versus reward doesn't appear to justify either a bullish or bearish position in JNJ. For most traders, there are likely better investments to be had than JNJ now, so I'd pencil the name as an avoid for now.

Tim Collins provides options trade ideas each day on Real Money Pro, our sister site for active traders. Click here to learn more and get great columns, commentary and trade ideas from Tim Collins, Mark Sebastian, Paul Price, Doug Kass, and others.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins had no positions in the securities mentioned.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long JNJ.

TAGS: Litigation | Earnings | Investing | Stocks | Trading | Healthcare | U.S. Equity | Stock of the Day

More from Stocks

When it Comes Time to Sell, Will You Act or Will You Freeze?

James "Rev Shark" DePorre
Jan 16, 2021 10:00 AM EST

Why don't more people embrace the ease and power of selling stocks? Why do they freeze and do nothing as losses build?

Hungry Traders and Stock Opportunities Aren't Likely to Go Away Soon

James "Rev Shark" DePorre
Jan 15, 2021 4:40 PM EST

It doesn't take much time for stocks with strong momentum to reset and continue on their way.

At What Price Is Ballard Power Systems a Buy?

Bruce Kamich
Jan 15, 2021 3:09 PM EST

Let's check out the latest charts of BLDP.

United Parcel Service Is Testing Key Support

Bruce Kamich
Jan 15, 2021 2:30 PM EST

A look at the charts of UPS.

A Buy and Hold Play With Hennessy Capital V

Timothy Collins
Jan 15, 2021 2:24 PM EST

HCICU hit the public markets today.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login